



JPW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/735,408  
Applicant: Storer *et al.*  
Filed: December 12, 2003  
TC/A.AU.: Unassigned  
Examiner: Unassigned

Confirmation No.: 2099

Docket No.: 06171.105101 IDX 1024  
Customer No.: 20786  
Title: Process for the Production of 2'-Branched Nucleosides

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Information Disclosure Statement

Sir:

The citation of information on the accompanying Form PTO-1449, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each reference is enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Applicants do not believe any fees are due because this paper is submitted before the mailing of a first Office action on the merits, as under 37 C.F.R. § 1.97(b)(3). However, the Commissioner is hereby authorized to charge any fees due or credit any overpayment to Deposit Account No. 11-0980.

Respectfully submitted,

*Sherry M. Knowles*  
*of c/o per [unclear] 36,174*  
Sherry M. Knowles  
Reg. No. 33,052


Dated: September 10, 2004  
King & Spalding, LLP  
191 Peachtree Street, N.E., Atlanta, GA 30303  
Office: (404)572-4600/ Fax: 404-572-5145

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on September 10, 2004.

*Brent R. Bellows*  
Brent R. Bellows

3524785\_1.DOC



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

1 of 8

**Complete if Known**

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer <i>et al.</i>
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3474020\_1.DOC

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear	T <sup>6</sup>
		Number	Kind Code (if known)				
	AA	3,798,209	A	Wilkowski, <i>et al.</i>	03-19-1974		
	AB	RE29,835		Wilkowski <i>et al.</i>	11-14-1978		
	AC	4,294,766	A	Schmidt <i>et al.</i>	10-13-1981		
	AD	4,522,811	A	Eppstein <i>et al.</i>	06-11-1985		
	AE	4,952,740	A	Juge <i>et al.</i>	08-28-1990		
	AF	4,957,924	A	Beauchamp	09-18-1990		
	AG	5,149,794	A	Yatvin <i>et al.</i>	09-22-1992		
	AH	5,157,027	A	Biller <i>et al.</i>	10-20-1992		
	AI	5,194,654	A	Hostetler <i>et al.</i>	03-16-1993		
	AJ	5,223,263	A	Hostetler <i>et al.</i>	06-29-1993		
	AK	5,256,641	A	Yatvin <i>et al.</i>	10-26-1993		
	AL	5,322,955	A	Matsumoto <i>et al.</i>	06-21-1994		
	AM	5,391,769	A	Matsumoto <i>et al.</i>	02-21-1995		
	AN	5,411,947	A	Hostetler <i>et al.</i>	05-02-1995		
	AO	5,463,092	A	Hostetler <i>et al.</i>	10-31-1995		
	AP	5,543,389	A	Yatvin <i>et al.</i>	08-06-1996		
	AQ	5,543,390	A	Yatvin <i>et al.</i>	08-06-1996		
	AR	5,543,391	A	Yatvin <i>et al.</i>	08-06-1996		
	AS	5,554,728	A	Basava <i>et al.</i>	09-10-1996		
	AT	6,153,594	A	Børretzen <i>et al.</i>	11-28-2000		
	AU	6,248,878	B1	Matulic-Adamic <i>et al.</i>	06-19-2001		
	AV	6,271,212	B1	Chu <i>et al.</i>	08-07-2001		
	AW	6,312,662	B1	Erion <i>et al.</i>	11-06-2001		
	AX	6,566,344	B1	Gosselin <i>et al.</i>	05-20-2003		
	AY	6,569,837	B1	Gosselin <i>et al.</i>	05-27-2003		
	AZ	2002/0019363	A1	Ismaili <i>et al.</i>	02-14-2002		
	AAA	2003/0050229	A1	Sommadossi <i>et al.</i>	03-13-2003		
	AAB	2003/0060400	A1	LaColla <i>et al.</i>	03-27-2003		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

2 of 8

**Complete if Known**

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer <i>et al.</i>
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3474020\_1.DOC

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
	BA	DE	3,512,781	A1	Soc. Nat. Elf Aquitaine	10-17-1985		Y
	BB	EP	0,180,276	B1	Stamicarbon B.V.	12-28-1988		
	BC	EP	0,350,287	A2	Vical Inc.	01-10-1990		
	BD	EP	0,526,655	A1	Japan Tobacco Inc.	02-10-1993		
	BE	EP	0,553,358	A1	Japan Tobacco Inc.	08-04-1993		
	BF	EP	0,650,371	B1	State of Oregon	05-03-1995		
	BG	JP	61-212592	A2	Tokyo Tanabe Co. Ltd.	09-20-1986		
	BH	WO	89/02733	A1	Regents of the Univ. of California	04-06-1989		
	BI	WO	90/00555	A1	Vical Inc.	01-25-1990		
	BJ	WO	91/16920	A1	Vical Inc.	11-14-1991		
	BK	WO	91/18914	A1	Vical Inc.	12-12-1991		
	BL	WO	91/19721	A1	Glazier	12-26-1991		
	BM	WO	93/00910	A1	Vical Inc.	01-21-1993		
	BN	WO	94/26273	A1	Hostetler	11-24-1994		
	BO	WO	96/15132	A1	Regents of the Univ. of California	05-23-1996		
	BP	WO	99/15194	A1	Schering Corporation	04-01-1999		
	BQ	WO	99/43691	A1	Emory; U. Georgia Res. Found.	09-02-1999		
	BR	WO	99/45016	A2	Metabasis Therapeutics Inc.	09-10-1999		
	BS	WO	99/59621	A1	Schering Corporation	11-25-1999		
	BT	WO	99/64016	A1	Hoffman-La Roche AG	12-16-1999		
	BU	WO	00/25799	A1	CNRS; UAB Res. Found.; Emory	05-11-2000		
	BV	WO	00/37110	A2	Schering Corporation	06-29-2000		
	BW	WO	00/52015	A2&3	Metabasis Therapeutics	09-08-2000		
	BX	WO	01/18013	A1	Metabasis Therapeutics	03-15-2001		
	BY	WO	01/32153	A2	Biochem Pharma	10-05-2001		
	BZ	WO	01/47935	A2	Metabasis Therapeutics	07-05-2001		
	BAA	WO	01/60315	A2	Biochem Pharma	08-23-2001		
	BAB	WO	01/79246	A2&3	Pharmasset	10-25-2001		
	BAC	WO	01/81359	A1	Schering Corporation	11-01-2000		
	BAD	WO	01/90121	A2&3	Novirio (Idenix); Univ. ... Cagliari	11-29-2000		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

3

of

8

**Complete if Known**

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer <i>et al.</i>
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3474020\_1.DOC

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>2</sup> (if known)				
	CA	WO	01/92282	A2&3	Novirio (Idenix); Univ. ... Cagliari	06-12-2001		
	CB	WO	01/96353	A2	Novirio Pharm. (Idenix); C.N.R.S.	21-20-2001		
	CC	WO	02/057287	A2	Merck; Isis Pharmaceuticals	07-25-2002		
	CD	WO	02/057425	A2	Merck; Isis Pharmaceuticals	07-25-2002		
	CE	WO	02/18404	A2	Hoffman-La Roche AG	03-07-2002		
	CF	WO	02/32414	A2	Schering Corporation	04-25-2002		
	CG	WO	02/32920	A2	Pharmasset	04-25-2002		
	CH	WO	02/48165	A2	Pharmasset	06-20-2002		
	CI	WO	03/024461	A1	Schering Corporation	03-27-2003		
	CJ	WO	04/003138	A2	Merck & Co., Isis Pharmaceutical	01-08-2004		
	CK	WO	04/009020	A2	Merck & Co., Isis Pharmaceutical	01-29-2004		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	CL	BAGINSKI, S. G. <i>et al.</i> , "Mechanism of action of a pestivirus antiviral compound," <i>PNAS USA</i> , 97(14): 7981-7986 (2000).	
	CM	BATTAGLIA, A.M. <i>et al.</i> , "Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection", <i>Ann. Pharmacother</i> , 34:487-494 (2000).	
	CN	BEIGELMAN, L.N., <i>et al.</i> , "Functionally complete analogues of nucleosides. The use of D-glucose for the synthesis of 2-C-methyl-D-ribose derivatives and related nucleosides," <i>Bioorg. Khim.</i> , 12(10):1359-1365 (1986). <i>Abstract in English at p. 1365.</i>	<i>Abstract in English at p. 1365</i>
	CO	BEIGELMAN, L.N., <i>et al.</i> , "New synthesis of 2'-C-methylnucleosides starting from D-glucose and D-ribose," <i>Carbohydrate Research</i> , 166:219-232 (1987).	
	CP	BENZARIA, S., <i>et al.</i> , "Synthesis of potential prodrugs of $\beta$ -L-dC, a potent and selective anti-HBV agent," <i>Antiviral Res.</i> , 50:A79 (2001).	
	CQ	BERENGUER, M. <i>et al.</i> , "Hepatitis C virus in the transplant setting", <i>Antivir. Ther.</i> , 3 (Suppl 3):125-136 (1998).	
	CR	BERMAN, E. <i>et al.</i> , "Synergistic cytotoxic effect of azidothymidine and recombinant interferon alpha on normal human bone marrow progenitor cells," <i>Blood</i> , 74(4):1281-1286 (1989)	
	CS	BHAT <i>et al.</i> (Oral Session V, Hepatitis C Virus, Flaviviridae, 2003 (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 <sup>th</sup> International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.); p A75).	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

4

of

8

**Complete if Known**

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer <i>et al.</i>
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3474020\_1.DOC

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	DA	BROWNE, M.J., <i>et al.</i> , "2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-Related Complex: A Phase I trial," <i>J. Infect. Dis.</i> , 167(1):21-29 (1993).	
	DB	BRYANT, M.L., <i>et al.</i> , "Antiviral L-nucleosides specific for hepatitis B virus infection," <i>Antimicrobial Agents and Chemotherapy</i> , 45(1):229-235 (January 2001).	
	DC	CAVELIER, F., <i>et al.</i> , "Studies of selective Boc removal in the presence of silyl ethers," <i>Tetrahedron Letters</i> , 37:5131-5134 (1996).	
	DD	COLACINO, J. M., "Review article: Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU)," <i>Antiviral Res.</i> , 29(2-3): 125-39 (1996).	
	DE	CRETTON-SCOTT, E., <i>et al.</i> , "Pharmacokinetics of $\beta$ -L-2'-deoxycytidine prodrugs in monkeys," <i>Antiviral Res.</i> , 50:A44 (2001).	
	DF	CUI, L., <i>et al.</i> , "Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1- $\beta$ -D-arabinofuranosyl)-5-iodouracil in human liver cells," <i>J. Clin. Invest.</i> , 95:555-563 (1995).	
	DG	DAVIS, G.L., "Current therapy for chronic Hepatitis C," <i>Gastroenterology</i> 118:S104-S114 (2000).	
	DH	De FRANCESCO, R., <i>et al.</i> , "Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase," <i>Antiviral Research</i> , 58: 1-16 (2003).	
	DI	De LOMBAERT, S., <i>et al.</i> , "N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors," <i>J. Med. Chem.</i> , 37:498-511 (1994).	
	DJ	DORNSIFE, R.E., <i>et al.</i> , "In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in Human Immunodeficiency Virus-positive humans," <i>Antimicrob. Agents Chemother.</i> , 40(2):514-519 (1996).	
	DK	DYMOCK, B.W., <i>et al.</i> , "Review: Novel approaches to the treatment of hepatitis C virus infection," <i>Antiviral Chemistry &amp; Chemotherapy</i> , 11(2):79-95 (2000).	
	DL	ELDRUP <i>et al.</i> (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 <sup>th</sup> International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.).	
	DM	FARKAS, J., <i>et al.</i> , "Nucleic acid components and their analogues. XCIV. Synthesis of 6-amino-9-(1-deoxy- $\beta$ -D-psicofuranosyl)purine", <i>Collect. Czech. Chem. Commun.</i> 32:2663-2667 (1967).	
	DN	FARKAS, J., <i>et al.</i> , "Nucleic acid components and their analogues. LXXIX. Synthesis of methyl 1-deoxy-D-psicofuranosides substituted at C <sub>(1)</sub> with halo atoms or a mercapto group," <i>Collect. Czech. Chem. Commun.</i> , 31:1535-1543 (1996).	
	DO	FARQUHAR, D., <i>et al.</i> , "Synthesis and biological evaluation of neutral derivatives of 3-fluoro-2'-deoxyuridine 5'-phosphate," <i>J. Med. Chem.</i> 26: 1153 (1983);	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

5

of

8

**Complete if Known**

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer <i>et al.</i>
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3474020\_1.DOC

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	EA	FARQUHAR, D., <i>et al.</i> , "Synthesis and biological evaluation of 9-[5'-(2-oxo-1,3,2-oxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine and 9-[5'-(2-oxo-1,3,2-dioxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine: Potential neutral precursors of 9-[β-D-arabinofuranosyl]adenine 5'-monophosphate," <i>J. Med. Chem.</i> 28:1358-1381 (1985).	
	EB	FEAST, A.A.J., <i>et al.</i> , "Studies on the D-glucosaccharinic acids," <i>Acta Chemica Scandinavica</i> 19(5):1127-1134 (1965).	
	EC	FERRARI R., <i>et al.</i> , "Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in <i>Escherichia coli</i> ," <i>Journal of Virology</i> , 73(2), 1649-1654 (1999).	
	ED	FISCHL, M.A., <i>et al.</i> , "Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy," <i>Ann. Intern. Med.</i> , 18(10):762-769 (1993).	
	EE	FREED, J.J., <i>et al.</i> , "Evidence for acyloxymethyl esters of pyrimidine 5'-deoxyribonucleotides as extracellular sources of active 5'-deoxyribonucleotides in cultured cells," <i>Biochemical Pharmacology</i> . 38:3193-3198 (1989).	
	EF	GUNIC, E., <i>et al.</i> , "Synthesis and cytotoxicity of 4'-C-and 5'-C-substituted Toyocamycins," <i>Bioorg. Med. Chem.</i> , 9:163-170 (2001).	
	EG	HARRY-O'KURU, R.E., J.M. Smith, and M.S. Wolfe, "A short, flexible route toward 2'-C-branched ribonucleosides," <i>J. Org. Chem.</i> 62, 1754-1759 (1997). (Scheme 11).	
	EH	HOSTETLER, K.Y., <i>et al.</i> , "Synthesis and antiretroviral activity of phospholipids analogs of azidothymidine and other antiviral nucleosides," <i>J. Biol. Chem.</i> , 265:6112-6117 (April 15, 1990)	
	EI	HOSTETLER, K.Y., <i>et al.</i> , "Greatly enhanced inhibition of Human Immunodeficiency Virus Type I replication in CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3'-deoxythymidine," <i>Antimicrob. Agents Chemother.</i> , 36:2025-2029 (September 1992).	
	EJ	HUNSTON, R.N., <i>et al.</i> , "Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine," <i>J. Med. Chem.</i> 27:440-444 (1984).	
	EK	JONES, G. H., and MOFFATT, J. G., "[55] Oxidation of carbohydrates by the sulfoxide-carbodiimide and related methods: Oxidation with dicyclohexylcarbodiimide-DMSO, diisopropylcarbodiimide-DMSO, acetic anhydride-DMSO, and phosphorus pentaoxide-DMSO," <i>Methods in Carbohydrate Chemistry</i> ; Whisler, R. L. and Moffatt, J. L. Eds; Academic Press: New York, 1972; 315-322	
	EL	JONES, G. H., <i>et al.</i> , "4'-substituted nucleosides. 5. Hydroxymethylation of nucleoside 5'-aldehydes," <i>J. Org. Chem.</i> , 44:1309-1317 (1979).	
	EM	KEMPE, T., <i>et al.</i> , "Selective 2'-benzoylation at the cis 2',3'-diols of protected ribonucleosides. New solid phase synthesis of RNA and DNA-RNA mixtures," <i>Nucleic Acids Res.</i> , 10(21):6695-6714 (November 11, 1982).	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/735,408
				Filing Date	December 12, 2003
				First Named Inventor	Storer <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Unassigned
6	of	8	Attorney Docket Number	06171.105101 IDX 1024	

3474020\_1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
	FA	KERR, S.G., <i>et al.</i> , "N <sup>4</sup> -(dialkylamino)methylene derivatives of 2'-deoxycytidine and arabinocytidine: physicochemical studies for potential prodrug applications," <i>J. Pharm. Sci.</i> , 83(4):582-586 (April 1994).		
	FB	KHAMNEI, S., "Neighboring group catalysis in the design of nucleotide prodrugs," <i>J. Med. Chem.</i> , 39:4109-4115 (1996).		
	FC	KILIANI, H., "Ueber Saccharin und Saccharinsäure," <i>Chemische Berichte</i> , 15:2953 (1882). In <i>German. Partial translation in English at pp. 43-44 of the SOWDEN reference.</i>	see SOWDEN	
	FD	KOHN, P., <i>et al.</i> , "A new method for the synthesis of furanose derivatives of aldohexoses," <i>J. Am. Chem. Soc.</i> , 87(23):5475-5480 (December 5, 1965).		
	FE	KUCERA, L.S., <i>et al.</i> , "Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation," <i>AIDS Res. Hum. Retro Viruses</i> , 6:491-501 (1990).		
	FF	KURTZBERG J., <i>et al.</i> , "Differential toxicity of carbovir and AZT to human bone marrow hematopoietic progenitor cells in vitro," <i>Exp. Hematol.</i> , 18(10):1094-1096 (1990).		
	FG	LEONARD, N. J., <i>et al.</i> , "5-Amino-5-deoxyribose derivatives. Synthesis and use in the preparation of "reversed" nucleosides" <i>J. Heterocycl. Chem.</i> , 3:485-489 (December 1966).		
	FH	LERZA, R., <i>et al.</i> , "In vitro synergistic inhibition of human bone marrow hemopoietic progenitor growth by a 3'-azido-3'-deoxy-thymidine, 2',3'-dideoxycytidine combination," <i>Exp. Hematol.</i> , 25(3):252-255 (1997).		
	FI	LEWIS, W., <i>et al.</i> , "Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria," <i>J. Clin. Invest.</i> , 89(4):1354-1360 (1992).		
	FJ	LEWIS, L. D., <i>et al.</i> , "Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2'3'-dideoxycytidine," <i>Antimicrob. Agents Chemother.</i> , 36(9):2061-2065 (1992).		
	FK	LEWIS, W., <i>et al.</i> , "Fialuridine and its metabolites inhibit DNA polymerase $\gamma$ at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts," <i>Proceedings of the National Academy of Sciences, USA</i> , 93(8): 3592-7 (1996).		
	FL	LI, N.-S., <i>et al.</i> , "2'-C-branched ribonucleosides. 2. Synthesis of 2'-C- $\beta$ -trifluoromethyl pyrimidine ribonucleosides," <i>Organic Letters</i> , 3(7):1025-1028 (2001).		
	FM	LOHMANN V., <i>et al.</i> , "Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the Hepatitis C virus," <i>Virology</i> , 249, 108-118 (1998).		
	FN	LOPEZ-HERRERA, F.J., <i>et al.</i> , "A new synthesis of 2-C-methyl-D-ribo-1,4-lactone and the C-(1C-13 fragment of methynolide," <i>J. Carbohydrate Chemistry</i> , 13(5):767-775 (1994).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

7

of

8

**Complete if Known**

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer <i>et al.</i>
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3474020\_1.DOC

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	GA	LOPEZ APARICIO, F.J., <i>et al.</i> , "Synthesis of saccharinic acid derivatives," <i>Carbohydrate Res.</i> , 129:99 (1984).	
	GB	LUH, T.-Y., <i>et al.</i> , "A convenient method for the selective esterification of amino-alcohols," <i>Synthetic Communications</i> , 8(5):327-333 (1978).	
	GC	McCORMICK, J., <i>et al.</i> , "Structure and total synthesis of HF-7, a neuroactive glyconucleoside disulfate from the funnel-web spider <i>Hololena curta</i> ," <i>J. Am. Chem. Soc.</i> , 121(24), 5661-5664 (1999).	
	GD	MCKENZIE, R., <i>et al.</i> , "Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B", <i>N. Engl. J. Med.</i> , 333(17):1099-1105 (1995).	
	GE	MEDINA, D. J., <i>et al.</i> , "Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-Human Immunodeficiency Virus dideoxynucleosides," <i>Antimicrob. Agents Chemother.</i> , 38(8):1824-8 (1994).	
	GF	MEIER, C., <i>et al.</i> , "Cyclic saligenyl phosphotriesters of 2',3'-dideoxy-2',3'-dideoxythymidine (d4T) – A new pro-nucleic approach." <i>Bioorganic &amp; Med. Chem. Letters</i> 7(2):99-104 (1997).	
	GG	MEYER, R.B., Jr., <i>et al.</i> , "2'-O-Acyl-6-thioinosine cyclic 3',5'-phosphates as prodrugs of thioinosinic acid," <i>J. Med. Chem.</i> 22: 811-815 (1979).	
	GH	NEIDLEIN, R., <i>et al.</i> , "Mild preparation of 1-benzyluloxyminoalkylphosphonic dichlorides: Application to the synthesis of cyclic phosphonic diesters and cyclic monoester amides," <i>Heterocycles</i> 35:1185-1203 (1993).	
	GI	NOVÁK, J.J.K. & SORM, F., "Nucleic acid components and their analogues. CXX. 2-C-methyl-D-ribose and its derivatives," <i>Collection Czechoslov. Chem. Commun.</i> , 34:857-866 (1969).	
	GJ	NOVÁK, J.J.K., "Chiroptical properties of 2-methyl-1,4-lactones; revised absolute configuration of 2-deoxy-2-C-methyl-erythro-D-pentono-1,4-lactones," <i>Collection Czechoslov. Chem. Commun.</i> , 39:869-882 (1974).	
	GK	NUTT, R.F., <i>et al.</i> , "Branched-chain sugar nucleosides. III. 3'-C-methyladenine", <i>J. Org. Chem.</i> , 33:1789-1795 (1968).	
	GL	OLSEN, <i>et al.</i> (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 <sup>th</sup> International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.) p A76).	
	GM	PAN-ZHOU, X-R, <i>et al.</i> , "Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells," <i>Antimicrob. Agents Chemother.</i> 44:496-503 (2000).	
	GN	PIANTADOSI, C., <i>et al.</i> , "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity," <i>J. Med. Chem.</i> 34:1408-1414 (1991).	
	GO	PIERRA, C., <i>et al.</i> , "Comparative studies of selected potential prodrugs of $\beta$ -L-dC, a potent and selective anti-HBV agent," <i>Antiviral Res.</i> , 50:A79 (2001), Abstract no. 138.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

8

of

8

**Complete if Known**

Application Number	10/735,408
Filing Date	December 12, 2003
First Named Inventor	Storer <i>et al.</i>
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	06171.105101 IDX 1024

3474020\_1.DOC

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	HA	RICHMAN, D.D., <i>et al.</i> , "The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-Related Complex," <i>N. Engl. J. Med.</i> , 317(4):192-197 (1987).	
	HB	SCHEIBLER, C., "Ueber das Saccharin und die Saccharinsäure," <i>Chemische Berichte</i> , 13:2212-2217 (1880). <i>In German.</i>	
	HC	SOMMADOSSI J-P, <i>et al.</i> , "Comparison of cytotoxicity of the (-)- and (+)- enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells," <i>Biochemical Pharmacology</i> 44(10):1921-1925 (1992).	
	HD	SOMMADOSSI J.-P., <i>et al.</i> , "Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro," <i>Antimicrobial Agents and Chemotherapy</i> , 31:452-454 (1987).	
	HE	SOWDEN, J., "The Saccharinic Acids," <i>Adv. Carbohydrate Chem.</i> , 12:43-46 (1957).	
	HF	STANDRING, D.N., <i>et al.</i> , "Antiviral beta-L-nucleosides specific for hepatitis B virus infection," <i>Antiviral Chem. &amp; Chemother.</i> , 12 (Suppl. 1):119-129 (2001).	
	HG	STARRETT, J.E.Jr., <i>et al.</i> , "Synthesis, oral bioavailability determination, and <i>in vitro</i> evaluation of prodrugs of the antiviral agents 9-(2-(phosphonomethoxy)ethyl]adenine (PMEA)," <i>J. Med. Chem.</i> 37: 1857-1864 (1994).	
	HH	TANG, X.-Q., <i>et al.</i> , "2'-C-branched ribonucleosides: Synthesis of the phosphoramidite derivatives of 2'-C- $\beta$ -methylcytidine and their incorporation into oligonucleotides," <i>J. Org. Chem.</i> , 64(3):747-754 (1999).	
	HI	WALTON, E., <i>et al.</i> , "Branched-chain sugar nucleosides. A new type of biologically active nucleoside," <i>J. Am. Chem. Soc.</i> , 88(19):4524-4525 (October 5, 1966).	
	HJ	WEINBERG, R.S., <i>et al.</i> , "Effect of antiviral drugs and hematopoietic growth factors on <i>in vitro</i> erythropoiesis," <i>Mt. Sinai J. Med.</i> 1998;65(1):5-13.	
	HK	WHISTLER, R.L., and BeMILLER, J.N., "[118] 'α'-D-Glucosaccharino-1,4-lactone," <i>Methods in Carbohydrate Chemistry</i> , 2:484-485 (1963).	
	HL	YARCHOAN, R., <i>et al.</i> , "Long-term toxicity / activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex," <i>The Lancet</i> , 336(8714):526-529 (1990).	
	HM	YOSHIDA Y, <i>et al.</i> , "Reversal of azidothymidine-induced bone marrow suppression by 2',3'-dideoxythymidine as studied by hemopoietic clonal culture," <i>AIDS Res. Hum. Retroviruses</i> , 6(7):929-932 (1990).	
	HN	ZON, G., "Cyclophosphamide Analogues," Chapter 4 in <u>Progress in Medicinal Chemistry</u> , Vol. 19, G.P. Ellis and G.B. West, Eds., pp. 205-246 (1982).	

Not available, but also not needed based on description in Sowden article:

Justus Liebigs Annalen Chemie, 213:361 (1883). KILIANI, H.,

BK

WO

00/24355

A1

Smith &amp; Nephew Kinetic

05-04-2000

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.